Back
 ABCR  Vol.5 No.1 , January 2016
Statins and Breast Cancer: An Overview of the Current Situation
Abstract: Statins [(3-hydroxy-3-methylglutaryl-coenzyme A reductase, HMG-CoA reductase, abbreviated HMGCR) inhibitors] inhibit cholesterol synthesis and are commonly used in the treatment and prevention of cardiovascular diseases. Preclinical and clinical studies have shown that the drug can be effective in several cancers including breast cancer which is the second most frequent cancer in the world and the commonest one among women. In breast cancer cell lines statins reduce proliferation, increase apoptosis, decrease invasion and sensitize them to radiation. Clinical trials in breast cancer patients have shown positive outcome in terms of decreased recurrence rate, decreased mortality and positive role as neoadjuvant agent. They may have a particular role in treatment-resistant cases like triple-negative or inflammatory breast cancer which have a poorer prognosis. There is also evidence of their potential use in metastatic bone disease from breast cancer. When statins inhibit 3-hydroxy-3-methylgutaryl CoA reductase which is the rate-limiting enzyme of the mevalonate pathway, the levels of mevalonate as well as its downstream products are decreased. Hence cancer growth is inhibited by reduced prenylation of CAAX proteins, N-Glycosylation of growth factor receptors and synthesis of membrane and steroid among others. Also statins are relatively cheap and can contribute to decrease the high cost of cancer treatment. However studies till now have not shown any association with decreased breast cancer incidence. In addition there are doubts regarding safety of statins when used over a prolonged period of time. Although statins are relatively safe with myotoxicity and hepatotoxicity being their major side effects, evidence regarding issues like drug interactions with anti-cancer drugs is lacking.
Cite this paper: Moonindranath, S. and Shen, H. (2016) Statins and Breast Cancer: An Overview of the Current Situation. Advances in Breast Cancer Research, 5, 14-29. doi: 10.4236/abcr.2016.51002.
References

[1]   Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. International Agency for Research on Cancer, Lyon.
http://globocan.iarc.fr

[2]   Guchelaar, H.J., Vermes, A., Vermes, I. and Haanen, C. (1997) Apoptosis: Molecular Mechanisms and Implications for Cancer Chemotherapy. Pharmacy World & Science, 19, 119-125.
http://dx.doi.org/10.1023/A:1008654316572

[3]   Bersot, T. (2011) Drug Therapy for Hypercholesterolemia and Dyslipidemia. In: Brunton, L.L., Chabner, B.A. and Knollman, B.C., Eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th Edition, McGraw-Hill, New York.

[4]   Farmer, J.A. (2000) Pleiotropic Effects of Statins. Current Atherosclerosis Reports, 2, 208-217.
http://dx.doi.org/10.1007/s11883-000-0022-3

[5]   Gotto Jr., A.M. and Farmer, J.A. (2001) Pleiotropic Effects of Statins: Do They Matter? Current Opinion in Lipidology, 12, 391-394.
http://dx.doi.org/10.1097/00041433-200108000-00004

[6]   LaRosa, J.C. (2001) Pleiotropic Effects of Statins and Their Clinical Significance. The American Journal of Cardiology, 88, 291-293.
http://dx.doi.org/10.1016/S0002-9149(01)01643-5

[7]   Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., Zeiher, A., Chaitman, B.R., Leslie, S. and Stern, T. (2001) Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial. JAMA, 285, 1711-1718.
http://dx.doi.org/10.1001/jama.285.13.1711

[8]   Mach, F. (2002) Toward a Role for Statins in Immunomodulation. Molecular Interventions, 2, 478-480.
http://dx.doi.org/10.1124/mi.2.8.478

[9]   Mulhaupt, F., Matter, C.M., Kwak, B.R., Pelli, G., Veillard, N.R., Burger, F., Graber, P., Luscher, T.F. and Mach, F. (2003) Statins (HMG-CoA Reductase Inhibitors) Reduce CD40 Expression in Human Vascular Cells. Cardiovascular Research, 59, 755-766.
http://dx.doi.org/10.1016/S0008-6363(03)00515-7

[10]   Bellosta, S., Ferri, N., Bernini, F., Paoletti, R. and Corsini, A. (2000) Non-Lipid-Related Effects of Statins. Annals of Medicine, 32, 164-176.
http://dx.doi.org/10.3109/07853890008998823

[11]   Hess, D.C. and Fagan, S.C. (2001) Pharmacology and Clinical Experience with Simvastatin. Expert Opinion on Pharmacotherapy, 2, 153-163.
http://dx.doi.org/10.1517/14656566.2.1.153

[12]   Niemi, M., Pasanen, M.K. and Neuvonen, P.J. (2011) Organic Anion Transporting Polypeptide 1B1: A Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews, 63, 157-181.
http://dx.doi.org/10.1124/pr.110.002857

[13]   Schachter, M. (2005) Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. Cardiovascular Drugs and Therapy, 19, 415-422.

[14]   Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H., Irie, S., Higuchi, S. and Sugiyama, Y. (2007) SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 82, 541-547.

[15]   Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R. and Bernini, F. (1999) New Insights into the Pharmacodynamic and Pharmacokinetic Properties of Statins. Pharmacology & Therapeutics, 84, 413-428.
http://dx.doi.org/10.1016/S0163-7258(99)00045-5

[16]   Bellosta, S., Paoletti, R. and Corsini, A. (2004) Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions. Circulation, 109, Iii50-Iii57.
http://dx.doi.org/10.1161/01.cir.0000131519.15067.1f

[17]   Shitara, Y. and Sugiyama, Y. (2006) Pharmacokinetic and Pharmacodynamic Alterations of 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors: Drug-Drug Interactions and Interindividual Differences in Transporter and Metabolic Enzyme Functions. Pharmacology & Therapeutics, 112, 71-105.
http://dx.doi.org/10.1016/j.pharmthera.2006.03.003

[18]   Hamelin, B.A. and Turgeon, J. (1998) Hydrophilicity/Lipophilicity: Relevance for the Pharmacology and Clinical Effects of HMG-CoA Reductase Inhibitors. Trends in Pharmacological Sciences, 19, 26-37.
http://dx.doi.org/10.1016/S0165-6147(97)01147-4

[19]   Fritz, G., Brachetti, C., Bahlmann, F., Schmidt, M. and Kaina, B. (2002) Rho GTPases in Human Breast Tumours: Expression and Mutation Analyses and Correlation with Clinical Parameters. British Journal of Cancer, 87, 635-644.
http://dx.doi.org/10.1038/sj.bjc.6600510

[20]   Konstantinopoulos, P.A., Karamouzis, M.V. and Papavassiliou, A.G. (2007) Post-Translational Modifications and Regulation of the RAS Superfamily of GTPases as Anticancer Targets. Nature Reviews: Drug Discovery, 6, 541-555.
http://dx.doi.org/10.1038/nrd2221

[21]   Keyomarsi, K., Sandoval, L., Band, V. and Pardee, A.B. (1991) Synchronization of Tumor and Normal Cells from G1 to Multiple Cell Cycles by Lovastatin. Cancer Research, 51, 3602-3609.

[22]   Campbell, M.J., Esserman, L.J., Zhou, Y., Shoemaker, M., Lobo, M., Borman, E., Baehner, F., Kumar, A.S., Adduci, K., Marx, C., Petricoin, E.F., Liotta, L.A., Winters, M., Benz, S. and Benz, C.C. (2006) Breast Cancer Growth Prevention by Statins. Cancer Research, 66, 8707-8714.
http://dx.doi.org/10.1158/0008-5472.CAN-05-4061

[23]   Kanugula, A.K., Gollavilli, P.N., Vasamsetti, S.B., Karnewar, S., Gopoju, R., Ummanni, R. and Kotamraju, S. (2014) Statin-Induced Inhibition of Breast Cancer Proliferation and Invasion Involves Attenuation of Iron Transport: Intermediacy of Nitric Oxide and Antioxidant Defence Mechanisms. The FEBS Journal, 281, 3719-3738.
http://dx.doi.org/10.1111/febs.12893

[24]   Luporsi, E., Andre, F., Spyratos, F., Martin, P.M., Jacquemier, J., Penault-Llorca, F., Tubiana-Mathieu, N., Sigal-Zafrani, B., Arnould, L., Gompel, A., Egele, C., Poulet, B., Clough, K.B., Crouet, H., Fourquet, A., Lefranc, J.P., Mathelin, C., Rouyer, N., Serin, D., Spielmann, M., Haugh, M., Chenard, M.P., Brain, E., de Cremoux, P. and Bellocq, J.P. (2012) Ki-67: Level of Evidence and Methodological Considerations for Its Role in the Clinical Management of Breast Cancer: Analytical and Critical Review. Breast Cancer Research and Treatment, 132, 895-915.
http://dx.doi.org/10.1007/s10549-011-1837-z

[25]   Lopez, F., Belloc, F., Lacombe, F., Dumain, P., Reiffers, J., Bernard, P. and Boisseau, M.R. (1991) Modalities of Synthesis of Ki67 Antigen during the Stimulation of Lymphocytes. Cytometry, 12, 42-49.
http://dx.doi.org/10.1002/cyto.990120107

[26]   Bjarnadottir, O., Romero, Q., Bendahl, P.O., Jirstrom, K., Ryden, L., Loman, N., Uhlen, M., Johannesson, H., Rose, C., Grabau, D. and Borgquist, S. (2013) Targeting HMG-CoA Reductase with Statins in a Window-of-Opportunity Breast Cancer Trial. Breast Cancer Research and Treatment, 138, 499-508.
http://dx.doi.org/10.1007/s10549-013-2473-6

[27]   Garwood, E.R., Kumar, A.S., Baehner, F.L., Moore, D.H., Au, A., Hylton, N., Flowers, C.I., Garber, J., Lesnikoski, B.A., Hwang, E.S., Olopade, O., Port, E.R., Campbell, M. and Esserman, L.J. (2010) Fluvastatin Reduces Proliferation and Increases Apoptosis in Women with High Grade Breast Cancer. Breast Cancer Research and Treatment, 119, 137-144.
http://dx.doi.org/10.1007/s10549-009-0507-x

[28]   Feldt, M., Bjarnadottir, O., Kimbung, S., Jirstrom, K., Bendahl, P.O., Veerla, S., Grabau, D., Hedenfalk, I. and Borgquist, S. (2015) Statin-Induced Anti-Proliferative Effects via Cyclin D1 and p27 in a Window-of-Opportunity Breast Cancer Trial. Journal of Translational Medicine, 13, 133.
http://dx.doi.org/10.1186/s12967-015-0486-0

[29]   Arnold, A. and Papanikolaou, A. (2005) Cyclin D1 in Breast Cancer Pathogenesis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 4215-4224.
http://dx.doi.org/10.1200/JCO.2005.05.064

[30]   Massague, J. (2004) G1 Cell-Cycle Control and Cancer. Nature, 432, 298-306.
http://dx.doi.org/10.1038/nature03094

[31]   Musgrove, E.A., Lee, C.S., Buckley, M.F. and Sutherland, R.L. (1994) Cyclin D1 Induction in Breast Cancer Cells Shortens G1 and Is Sufficient for Cells Arrested in G1 to Complete the Cell Cycle. Proceedings of the National Academy of Sciences of the United States of America, 91, 8022-8026.
http://dx.doi.org/10.1073/pnas.91.17.8022

[32]   Blain, S.W. (2008) Switching Cyclin D-Cdk4 Kinase Activity On and Off. Cell Cycle, 7, 892-898.
http://dx.doi.org/10.4161/cc.7.7.5637

[33]   Chu, I.M., Hengst, L. and Slingerland, J.M. (2008) The Cdk Inhibitor p27 in Human Cancer: Prognostic Potential and Relevance to Anticancer Therapy. Nature Reviews: Cancer, 8, 253-267.
http://dx.doi.org/10.1038/nrc2347

[34]   Guan, X., Wang, Y., Xie, R., Chen, L., Bai, J., Lu, J. and Kuo, M.T. (2010) p27(Kip1) as a Prognostic Factor in Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Cellular and Molecular Medicine, 14, 944-953.
http://dx.doi.org/10.1111/j.1582-4934.2009.00730.x

[35]   Chang, L. and Karin, M. (2001) Mammalian MAP Kinase Signalling Cascades. Nature, 410, 37-40.
http://dx.doi.org/10.1038/35065000

[36]   Koyuturk, M., Ersoz, M. and Altiok, N. (2007) Simvastatin Induces Apoptosis in Human Breast Cancer Cells: p53 and Estrogen Receptor Independent Pathway Requiring Signalling through JNK. Cancer Letters, 250, 220-228.
http://dx.doi.org/10.1016/j.canlet.2006.10.009

[37]   Brozovic, A., Fritz, G., Christmann, M., Zisowsky, J., Jaehde, U., Osmak, M. and Kaina, B. (2004) Long-Term Activation of SAPK/JNK, p38 Kinase and Fas-L Expression by Cisplatin Is Attenuated in Human Carcinoma Cells That Acquired Drug Resistance. International Journal of Cancer, 112, 974-985.

[38]   Brantley-Finley, C., Lyle, C.S., Du, L., Goodwin, M.E., Hall, T., Szwedo, D., Kaushal, G.P. and Chambers, T.C. (2003) The JNK, ERK and p53 Pathways Play Distinct Roles in Apoptosis Mediated by the Antitumor Agents Vinblastine, Doxorubicin, and Etoposide. Biochemical Pharmacology, 66, 459-469.
http://dx.doi.org/10.1016/S0006-2952(03)00255-7

[39]   Gopalan, A., Yu, W., Sanders, B.G. and Kline, K. (2013) Simvastatin Inhibition of Mevalonate Pathway Induces Apoptosis in Human Breast Cancer Cells via Activation of JNK/CHOP/DR5 Signaling Pathway. Cancer Letters, 329, 9-16.
http://dx.doi.org/10.1016/j.canlet.2012.08.031

[40]   Ghosh-Choudhury, N., Mandal, C.C., Ghosh-Choudhury, N. and Ghosh Choudhury, G. (2010) Simvastatin Induces Derepression of PTEN Expression via NFκB to Inhibit Breast Cancer Cell Growth. Cellular Signalling, 22, 749-758.
http://dx.doi.org/10.1016/j.cellsig.2009.12.010

[41]   Aberg, M., Wickstrom, M. and Siegbahn, A. (2008) Simvastatin Induces Apoptosis in Human Breast Cancer Cells in a NFκB-Dependent Manner and Abolishes the Anti-Apoptotic Signaling of TF/FVIIa and TF/FVIIa/FXa. Thrombosis Research, 122, 191-202.
http://dx.doi.org/10.1016/j.thromres.2007.09.017

[42]   Denoyelle, C., Vasse, M., Korner, M., Mishal, Z., Ganne, F., Vannier, J.P., Soria, J. and Soria, C. (2001) Cerivastatin, an Inhibitor of HMG-CoA Reductase, Inhibits the Signaling Pathways Involved in the Invasiveness and Metastatic Properties of Highly Invasive Breast Cancer Cell Lines: An in Vitro Study. Carcinogenesis, 22, 1139-1148.
http://dx.doi.org/10.1093/carcin/22.8.1139

[43]   Alonso, D.F., Farina, H.G., Skilton, G., Gabri, M.R., De Lorenzo, M.S. and Gomez, D.E. (1998) Reduction of Mouse Mammary Tumor Formation and Metastasis by Lovastatin, an Inhibitor of the Mevalonate Pathway of Cholesterol Synthesis. Breast Cancer Research and Treatment, 50, 83-93.
http://dx.doi.org/10.1023/A:1006058409974

[44]   Rachner, T.D., Gobel, A., Thiele, S., Rauner, M., Benad-Mehner, P., Hadji, P., Bauer, T., Muders, M.H., Baretton, G.B., Jakob, F., Ebert, R., Bornhauser, M., Schem, C. and Hofbauer, L.C. (2014) Dickkopf-1 Is Regulated by the Mevalonate Pathway in Breast Cancer. Breast Cancer Research: BCR, 16, R20.
http://dx.doi.org/10.1186/bcr3616

[45]   Gobel, A., Browne, A.J., Thiele, S., Rauner, M., Hofbauer, L.C. and Rachner, T.D. (2015) Potentiated Suppression of Dickkopf-1 in Breast Cancer by Combined Administration of the Mevalonate Pathway Inhibitors Zoledronic Acid and Statins. Breast Cancer Research and Treatment, 154, 623-631.
http://dx.doi.org/10.1007/s10549-015-3624-8

[46]   Xu, W.H., Liu, Z.B., Yang, C., Qin, W. and Shao, Z.M. (2012) Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype. PloS ONE, 7, e37624.
http://dx.doi.org/10.1371/journal.pone.0037624

[47]   Voorzanger-Rousselot, N., Goehrig, D., Journe, F., Doriath, V., Body, J.J., Clezardin, P. and Garnero, P. (2007) Increased Dickkopf-1 Expression in Breast Cancer Bone Metastases. British Journal of Cancer, 97, 964-970.
http://dx.doi.org/10.1038/sj.bjc.6603959

[48]   Hamalukic, M., Huelsenbeck, J., Schad, A., Wirtz, S., Kaina, B. and Fritz, G. (2011) Rac1-Regulated Endothelial Radiation Response Stimulates Extravasation and Metastasis That Can Be Blocked by HMG-CoA Reductase Inhibitors. PloS ONE, 6, e26413.
http://dx.doi.org/10.1371/journal.pone.0026413

[49]   Chan, K.K., Oza, A.M. and Siu, L.L. (2003) The Statins as Anticancer Agents. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 9, 10-19.

[50]   Pazzaglia, S., Saran, A., Pariset, L., Rebessi, S., Di Majo, V., Coppola, M. and Covelli, V. (1996) Sensitivity of C3H 10T1/2 Cells to Radiation-Induced Killing and Neoplastic Transformation as a Function of Cell Cycle. International Journal of Radiation Biology, 69, 57-65.
http://dx.doi.org/10.1080/095530096146183

[51]   Langley, R.E., Quartuccio, S.G., Kennealey, P.T., Coleman, C.N. and Bump, E.A. (1995) Effect of Cell Cycle Stage, Dose Rate and Repair of Sublethal Damage on Radiation-Induced Apoptosis in F9 Teratocarcinoma Cells. Radiation Research, 144, 90-96.
http://dx.doi.org/10.2307/3579240

[52]   Lacerda, L., Reddy, J.P., Liu, D., Larson, R., Li, L., Masuda, H., Brewer, T., Debeb, B.G., Xu, W., Hortobagyi, G.N., Buchholz, T.A., Ueno, N.T. and Woodward, W.A. (2014) Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated with Improved Local Control in Inflammatory Breast Cancer Patients Treated with Postmastectomy Radiation. Stem Cells Translational Medicine, 3, 849-856.
http://dx.doi.org/10.5966/sctm.2013-0204

[53]   Nubel, T., Dippold, W., Kaina, B. and Fritz, G. (2004) Ionizing Radiation-Induced E-Selectin Gene Expression and Tumor Cell Adhesion Is Inhibited by Lovastatin and All-Trans Retinoic Acid. Carcinogenesis, 25, 1335-1344.
http://dx.doi.org/10.1093/carcin/bgh133

[54]   Nubel, T., Dippold, W., Kleinert, H., Kaina, B. and Fritz, G. (2004) Lovastatin Inhibits Rho-Regulated Expression of E-Selectin by TNFalpha and Attenuates Tumor Cell Adhesion. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 18, 140-142.

[55]   Ostrau, C., Hulsenbeck, J., Herzog, M., Schad, A., Torzewski, M., Lackner, K.J. and Fritz, G. (2009) Lovastatin Attenuates Ionizing Radiation-Induced Normal Tissue Damage in Vivo. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 92, 492-499.

[56]   Wang, J., Boerma, M., Fu, Q., Kulkarni, A., Fink, L.M. and Hauer-Jensen, M. (2007) Simvastatin Ameliorates Radiation Enteropathy Development after Localized, Fractionated Irradiation by a Protein C-Independent Mechanism. International Journal of Radiation Oncology, Biology, Physics, 68, 1483-1490.
http://dx.doi.org/10.1016/j.ijrobp.2007.03.036

[57]   Haydont, V., Bourgier, C., Pocard, M., Lusinchi, A., Aigueperse, J., Mathe, D., Bourhis, J. and Vozenin-Brotons, M.C. (2007) Pravastatin Inhibits the Rho/CCN2/Extracellular Matrix Cascade in Human Fibrosis Explants and Improves Radiation-Induced Intestinal Fibrosis in Rats. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 13, 5331-5340.

[58]   Monceau, V., Pasinetti, N., Schupp, C., Pouzoulet, F., Opolon, P. and Vozenin, M.C. (2010) Modulation of the Rho/ROCK Pathway in Heart and Lung after Thorax Irradiation Reveals Targets to Improve Normal Tissue Toxicity. Current Drug Targets, 11, 1395-1404.
http://dx.doi.org/10.2174/1389450111009011395

[59]   Kwan, M.L., Habel, L.A., Flick, E.D., Quesenberry, C.P. and Caan, B. (2008) Post-Diagnosis Statin Use and Breast Cancer Recurrence in a Prospective Cohort Study of Early Stage Breast Cancer Survivors. Breast Cancer Research and Treatment, 109, 573-579.
http://dx.doi.org/10.1007/s10549-007-9683-8

[60]   Ahern, T.P., Pedersen, L., Tarp, M., Cronin-Fenton, D.P., Garne, J.P., Silliman, R.A., Sorensen, H.T. and Lash, T.L. (2011) Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study. Journal of the National Cancer Institute, 103, 1461-1468.
http://dx.doi.org/10.1093/jnci/djr291

[61]   Chae, Y.K., Valsecchi, M.E., Kim, J., Bianchi, A.L., Khemasuwan, D., Desai, A. and Tester, W. (2011) Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins. Cancer Investigation, 29, 585-593.
http://dx.doi.org/10.3109/07357907.2011.616252

[62]   Chubak, J., Boudreau, D.M., Wirtz, H.S., McKnight, B. and Weiss, N.S. (2013) Threats to Validity of Nonrandomized Studies of Postdiagnosis Exposures on Cancer Recurrence and Survival. Journal of the National Cancer Institute, 105, 1456-1462.
http://dx.doi.org/10.1093/jnci/djt211

[63]   Lash, T.L. and Cole, S.R. (2009) Immortal Person-Time in Studies of Cancer Outcomes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, e55-e56.
http://dx.doi.org/10.1200/jco.2009.24.1877

[64]   Nickels, S., Vrieling, A., Seibold, P., Heinz, J., Obi, N., Flesch-Janys, D. and Chang-Claude, J. (2013) Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort. PloS ONE, 8, e75088.
http://dx.doi.org/10.1371/journal.pone.0075088

[65]   Boudreau, D.M., Yu, O., Chubak, J., Wirtz, H.S., Bowles, E.J., Fujii, M. and Buist, D.S. (2014) Comparative Safety of Cardiovascular Medication Use and Breast Cancer Outcomes among Women with Early Stage Breast Cancer. Breast Cancer Research and Treatment, 144, 405-416.
http://dx.doi.org/10.1007/s10549-014-2870-5

[66]   Borgquist, S., Djerbi, S., Ponten, F., Anagnostaki, L., Goldman, M., Gaber, A., Manjer, J., Landberg, G. and Jirstrom, K. (2008) HMG-CoA Reductase Expression in Breast Cancer Is Associated with a Less Aggressive Phenotype and Influenced by Anthropometric Factors. International Journal of Cancer, 123, 1146-1153.
http://dx.doi.org/10.1002/ijc.23597

[67]   Murtola, T.J., Visvanathan, K., Artama, M., Vainio, H. and Pukkala, E. (2014) Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland. PloS ONE, 9, e110231.
http://dx.doi.org/10.1371/journal.pone.0110231

[68]   Cardwell, C.R., Hicks, B.M., Hughes, C. and Murray, L.J. (2015) Statin Use after Diagnosis of Breast Cancer and Survival: A Population-Based Cohort Study. Epidemiology, 26, 68-78.
http://dx.doi.org/10.1097/EDE.0000000000000189

[69]   Zhong, S., Zhang, X., Chen, L., Ma, T., Tang, J. and Zhao, J. (2015) Statin Use and Mortality in Cancer Patients: Systematic Review and Meta-Analysis of Observational Studies. Cancer Treatment Reviews, 41, 554-567.
http://dx.doi.org/10.1016/j.ctrv.2015.04.005

[70]   Hance, K.W., Anderson, W.F., Devesa, S.S., Young, H.A. and Levine, P.H. (2005) Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. Journal of the National Cancer Institute, 97, 966-975.
http://dx.doi.org/10.1093/jnci/dji172

[71]   Gonzalez-Angulo, A.M., Hennessy, B.T., Broglio, K., Meric-Bernstam, F., Cristofanilli, M., Giordano, S.H., Buchholz, T.A., Sahin, A., Singletary, S.E., Buzdar, A.U. and Hortobagyi, G.N. (2007) Trends for Inflammatory Breast Cancer: Is Survival Improving? The Oncologist, 12, 904-912.
http://dx.doi.org/10.1634/theoncologist.12-8-904

[72]   Brewer, T.M., Masuda, H., Liu, D.D., Shen, Y., Liu, P., Iwamoto, T., Kai, K., Barnett, C.M., Woodward, W.A., Reuben, J.M., Yang, P., Hortobagyi, G.N. and Ueno, N.T. (2013) Statin Use in Primary Inflammatory Breast Cancer: A Cohort Study. British Journal of Cancer, 109, 318-324.
http://dx.doi.org/10.1038/bjc.2013.342

[73]   Lazar, L.D., Pletcher, M.J., Coxson, P.G., Bibbins-Domingo, K. and Goldman, L. (2011) Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era. Circulation, 124, 146-153.
http://dx.doi.org/10.1161/CIRCULATIONAHA.110.986349

[74]   Sprague, J.R. and Wood, M.E. (2006) Statins and Breast Cancer Prevention: Time for Randomized Controlled Trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24, 2129-2130, Author Reply 2130-2131.
http://dx.doi.org/10.1200/JCO.2005.05.5392

[75]   Bonovas, S., Filioussi, K., Tsavaris, N. and Sitaras, N.M. (2005) Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 8606-8612.
http://dx.doi.org/10.1200/JCO.2005.02.7045

[76]   Dale, K.M., Coleman, C.I., Henyan, N.N., Kluger, J. and White, C.M. (2006) Statins and Cancer Risk: A Meta-Analysis. JAMA, 295, 74-80.
http://dx.doi.org/10.1001/jama.295.1.74

[77]   Browning, D.R. and Martin, R.M. (2007) Statins and Risk of Cancer: A Systematic Review and Metaanalysis. International Journal of Cancer, 120, 833-843.
http://dx.doi.org/10.1002/ijc.22366

[78]   Kuoppala, J., Lamminpaa, A. and Pukkala, E. (2008) Statins and Cancer: A Systematic Review and Meta-Analysis. European Journal of Cancer, 44, 2122-2132.
http://dx.doi.org/10.1016/j.ejca.2008.06.025

[79]   Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., Keech, A., Simes, J. and Collins, R. (2010) Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. The Lancet, 376, 1670-1681.
http://dx.doi.org/10.1016/S0140-6736(10)61350-5

[80]   Undela, K., Srikanth, V. and Bansal, D. (2012) Statin Use and Risk of Breast Cancer: A Meta-Analysis of Observational Studies. Breast Cancer Research and Treatment, 135, 261-269.
http://dx.doi.org/10.1007/s10549-012-2154-x

[81]   Bjerre, L.M. and LeLorier, J. (2001) Do Statins Cause Cancer? A Meta-Analysis of Large Randomized Clinical Trials. The American Journal of Medicine, 110, 716-723.
http://dx.doi.org/10.1016/S0002-9343(01)00705-7

[82]   Hebert, P.R., Gaziano, J.M., Chan, K.S. and Hennekens, C.H. (1997) Cholesterol Lowering with Statin Drugs, Risk of Stroke, and Total Mortality. An Overview of Randomized Trials. JAMA, 278, 313-321.
http://dx.doi.org/10.1001/jama.1997.03550040069040

[83]   Law, M.R., Thompson, S.G. and Wald, N.J. (1994) Assessing Possible Hazards of Reducing Serum Cholesterol. BMJ, 308, 373-379.
http://dx.doi.org/10.1136/bmj.308.6925.373

[84]   Jacobs, D., Blackburn, H., Higgins, M., Reed, D., Iso, H., McMillan, G., Neaton, J., Nelson, J., Potter, J., Rifkind, B., et al. (1992) Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation, 86, 1046-1060.
http://dx.doi.org/10.1161/01.CIR.86.3.1046

[85]   Newman, T.B. and Hulley, S.B. (1996) Carcinogenicity of Lipid-Lowering Drugs. JAMA, 275, 55-60.
http://dx.doi.org/10.1001/jama.1996.03530250059028

[86]   Kritchevsky, S.B. (1992) Dietary Lipids and the Low Blood Cholesterol-Cancer Association. American Journal of Epidemiology, 135, 509-520.

[87]   Eichholzer, M., Stahelin, H.B., Gutzwiller, F., Ludin, E. and Bernasconi, F. (2000) Association of Low Plasma Cholesterol with Mortality for Cancer at Various Sites in Men: 17-y Follow-Up of the Prospective Basel Study. The American Journal of Clinical Nutrition, 71, 569-574.

[88]   Dalenc, F., Giamarchi, C., Petit, M., Poirot, M., Favre, G. and Faye, J.C. (2005) Farnesyl-Transferase Inhibitor R115,777 Enhances Tamoxifen Inhibition of MCF-7 Cell Growth through Estrogen Receptor Dependent and Independent Pathways. Breast Cancer Research: BCR, 7, R1159-R1167.
http://dx.doi.org/10.1186/bcr1357

[89]   Schachter, M. (2005) Chemical, Pharmacokinetic and Pharmacodynamic Properties of Statins: An Update. Fundamental & Clinical Pharmacology, 19, 117-125.
http://dx.doi.org/10.1111/j.1472-8206.2004.00299.x

[90]   Duncan, R.E., El-Sohemy, A. and Archer, M.C. (2004) Mevalonate Promotes the Growth of Tumors Derived from Human Cancer Cells in Vivo and Stimulates Proliferation in Vitro with Enhanced Cyclin-Dependent Kinase-2 Activity. The Journal of Biological Chemistry, 279, 33079-33084.
http://dx.doi.org/10.1074/jbc.M400732200

[91]   Duncan, R.E., El-Sohemy, A. and Archer, M.C. (2005) Statins and Cancer Development. Cancer Epidemiology, Biomarkers & Prevention, 14, 1897-1898.
http://dx.doi.org/10.1158/1055-9965.EPI-05-0027

[92]   van Vliet, A.K., van Thiel, G.C., Huisman, R.H., Moshage, H., Yap, S.H. and Cohen, L.H. (1995) Different Effects of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors on Sterol Synthesis in Various Human Cell Types. Biochimica et Biophysica Acta, 1254, 105-111.
http://dx.doi.org/10.1016/0005-2760(94)00176-Y

[93]   Pedersen, T.R., Wilhelmsen, L., Faergeman, O., Strandberg, T.E., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T.J., Haghfelt, T., Kjekshus, J., Miettinen, T., Olsson, A.G., Pyorala, K. and Wedel, H. (2000) Follow-Up Study of Patients Randomized in the Scandinavian Simvastatin Survival Study (4S) of Cholesterol Lowering. The American Journal of Cardiology, 86, 257-262.
http://dx.doi.org/10.1016/S0002-9149(00)00910-3

[94]   Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W. and Gotto Jr., A.M. (1998) Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279, 1615-1622.
http://dx.doi.org/10.1001/jama.279.20.1615

[95]   McDougall, J.A., Malone, K.E., Daling, J.R., Cushing-Haugen, K.L., Porter, P.L. and Li, C.I. (2013) Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age. Cancer Epidemiology, Biomarkers & Prevention, 22, 1529-1537.
http://dx.doi.org/10.1158/1055-9965.EPI-13-0414

[96]   Wilke, R.A., Lin, D.W., Roden, D.M., Watkins, P.B., Flockhart, D., Zineh, I., Giacomini, K.M. and Krauss, R.M. (2007) Identifying Genetic Risk Factors for Serious Adverse Drug Reactions: Current Progress and Challenges. Nature Reviews: Drug Discovery, 6, 904-916.
http://dx.doi.org/10.1038/nrd2423

[97]   Baker, S.K. and Tarnopolsky, M.A. (2001) Statin Myopathies: Pathophysiologic and Clinical Perspectives. Clinical and Investigative Medicine, 24, 258-272.

[98]   Thompson, P.D., Clarkson, P. and Karas, R.H. (2003) Statin-Associated Myopathy. JAMA, 289, 1681-1690.
http://dx.doi.org/10.1001/jama.289.13.1681

[99]   Walravens, P.A., Greene, C. and Frerman, F.E. (1989) Lovastatin, Isoprenes, and Myopathy. The Lancet, 2, 1097-1098.
http://dx.doi.org/10.1016/S0140-6736(89)91108-2

[100]   Chariot, P., Abadia, R., Agnus, D., Danan, C., Charpentier, C. and Gherardi, R.K. (1993) Simvastatin-Induced Rhabdomyolysis Followed by a MELAS Syndrome. The American Journal of Medicine, 94, 109-110.
http://dx.doi.org/10.1016/0002-9343(93)90129-D

[101]   Banach, M., Serban, C., Sahebkar, A., Ursoniu, S., Rysz, J., Muntner, P., Toth, P.P., Jones, S.R., Rizzo, M., Glasser, S.P., Lip, G.Y., Dragan, S. and Mikhailidis, D.P. (2015) Effects of Coenzyme Q10 on Statin-Induced Myopathy: A Meta-Analysis of Randomized Controlled Trials. Mayo Clinic Proceedings, 90, 24-34.
http://dx.doi.org/10.1016/j.mayocp.2014.08.021

[102]   Maron, D.J., Fazio, S. and Linton, M.F. (2000) Current Perspectives on Statins. Circulation, 101, 207-213.
http://dx.doi.org/10.1161/01.CIR.101.2.207

[103]   Farmer, J.A. and Torre-Amione, G. (2000) Comparative Tolerability of the HMG-CoA Reductase Inhibitors. Drug Safety, 23, 197-213.
http://dx.doi.org/10.2165/00002018-200023030-00003

 
 
Top